ENTX · XBRL financial data

Entera Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ENTX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	0*	0	57	42	82*	42	0	0	0*	0	0
Cost of revenue	0	0*	0	48	42	82*	42	0	0	0*	0	0
Gross profit	0	0*	—	9	0	0*	0	0	0	0*	0	0
Research and development	1,370	1,000*	735	1,086	1,477	1,201*	1,123	1,520	1,643	1,718*	2,251	3,201
Selling, general and administrative	—	—	—	134	62	96*	123	103	122	54*	128	124
General and administrative	1,028	973*	1,327	1,088	1,544	1,136*	1,440	1,148	1,613	1,324*	1,288	1,362
Total operating expenses	2,386	1,963*	2,062	2,174	3,021	2,337*	2,563	2,668	3,256	3,042*	3,539	4,563
Operating income (loss)	(2,386)	(1,963)*	(2,062)	(2,165)	(3,021)	(2,337)*	(2,563)	(2,668)	(3,256)	(3,042)*	(3,539)	(4,563)
Income tax expense (benefit)	29	0*	—	—	0	14*	—	—	—	year only	—	—
Net income (loss)	(2,379)	(1,995)*	(2,017)	(2,145)	(3,021)	(2,358)*	(2,567)	(2,656)	(3,200)	(3,016)*	(3,505)	(7,312)
Earnings per share, basic USD per share	0.08	—	0.05	0.06	0.08	—	0.06	0.06	0.07	—	0.07	0.14
Earnings per share, diluted USD per share	0.08	—	0.05	0.06	0.08	—	0.06	0.06	0.07	—	0.07	0.14
Weighted average shares, basic thousands of shares	28,814	29,589*	36,735	37,090	37,645	39,114*	43,377	46,837	47,090	47,406*	47,756	50,451
Weighted average shares, diluted thousands of shares	28,814	29,589*	36,735	37,090	37,645	39,114*	43,377	46,837	47,090	47,406*	47,756	50,451

Fiscal quarters (ENTX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	7,585	11,019	9,189	9,056	6,915	8,660	12,573	10,858	8,574	7,108	4,137	11,309
Accounts receivable	0	0	—	57	42	126	126	0	0	0	—	—
Prepaid and other current assets	431	238	562	482	383	186	519	438	405	415	566	465
Total current assets	8,016	11,257	9,751	9,595	7,340	8,972	21,218	19,311	17,007	15,298	12,493	18,896
Property and equipment, net	108	100	87	76	65	57	57	79	114	134	127	121
Right-of-use asset	420	388	381	344	316	275	227	190	194	465	413	362
Total assets	8,565	11,765	10,239	10,035	7,741	9,390	21,600	19,667	17,407	15,993	13,129	19,480
Accounts payable	564	83	66	69	184	132	134	383	216	448	274	575
Total current liabilities	2,027	1,091	1,121	1,294	1,111	1,176	1,623	1,844	1,571	2,203	1,576	2,104
Lease liability, non-current	271	256	224	179	147	102	51	9	41	260	263	226
Total liabilities	2,329	1,379	1,376	1,503	1,289	1,310	2,221	2,411	2,173	2,892	2,442	12,214
Accumulated deficit	(102,391)	(104,386)	(106,403)	(108,548)	(111,569)	(113,927)	(116,494)	(119,150)	(122,350)	(125,366)	(128,871)	(136,183)
Total stockholders' equity	6,236	10,386	8,863	8,532	6,452	8,080	19,379	17,256	15,234	13,101	10,687	7,266
Total liabilities and equity	8,565	11,765	10,239	10,035	7,741	9,390	21,600	19,667	17,407	15,993	13,129	19,480
Common shares outstanding (cover page) thousands of shares	28,814	35,481	35,785	36,325	36,832	45,421	45,452	45,663	45,857	46,622	49,225	173,142

Fiscal quarters (ENTX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,379)	(1,995)*	(2,017)	(2,145)	(3,021)	(2,358)*	(2,567)	(2,656)	(3,200)	(3,016)*	(3,505)	(7,312)
Stock-based compensation	383*	318*	464	598*	928*	566*	604	509*	927*	710*	672	624*
Net cash from operating activities	(1,525)*	(2,617)*	(1,862)	(1,335)*	(2,154)*	(1,467)*	(1,404)	(1,631)*	(2,502)*	(1,833)*	(3,090)	(3,464)*
Purchases of property and equipment	0*	5*	0	0*	0*	3*	8	29*	43*	27*	0	3*
Net cash from investing activities	0*	(5)*	0	0*	0*	(3)*	(8)	(29)*	(43)*	(27)*	0	(3)*
Proceeds from issuing common stock	0*	0*	0	601*	0*	3,359*	6,183	0*	71*	0*	0	0*
Net cash from financing activities	0*	6,031*	30	1,216*	13*	3,217*	13,337	(51)*	250*	174*	130	9,959*
Net change in cash	(1,525)*	3,409*	(1,832)	(119)*	(2,141)*	1,747*	11,925	(1,711)*	—	year only	—	—

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Entera Bio	11,309	0	(3,464)*	173.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Anixa Biosciences	1,398	not reported	(1,770)*	34.8M	6.8 quarters	Q3 FY26 10-QJul 31, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Filana Therapeutics	46,990	not reported	(6,094)*	50.3M	7.5 quarters	Q3 FY26 10-QSep 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	30,900	not reported	(10,364)*	28.3M	3.1 quarters	Q3 FY26 10-QSep 30, 2026
GENELUX	9,184	not reported	(6,444)*	45.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	189.8 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:50 PM ET. The filing on SEC.gov is the record.